Indications for INJECTAFER:

Iron deficiency anemia in adults who have intolerance or insufficient response to oral iron; or have non-dialysis-dependent chronic kidney disease.


Give by slow IV push (undiluted) at rate of approx. 100mg (2mL)/min; or by IV infusion (diluted) administered over at least 15 mins. When giving via IV infusion, dilute to concentration not less than 2mg iron/mL. Give in 2 doses separated by >7 days. <50kg: 15mg/kg/dose. ≥50kg: 750mg/dose. Total cumulative dose per course: max 1500mg. May repeat treatment if condition reoccurs.


Not established.


Monitor for hypersensitivity reactions during and after administration for ≥30mins and until clinically stable. Have epinephrine inj immediately available. Possible risk for hypophosphatemia if history of GI disorders associated with malabsorption of fat-soluble vitamins or phosphate, hyperparathyroidism, vitamin D deficiency, malnutrition. Monitor serum phosphate levels in at-risk patients who require a repeat course. Monitor for hypertension after each administration. Avoid extravasation. Pregnancy. Nursing mothers: monitor infants for GI toxicity.

Pharmacologic Class:



Caution with concurrent or prior use of drugs that affect proximal renal tubular function. Lab assays may overestimate serum iron and transferrin bound iron within 24hrs after administration.

Adverse Reactions:

Nausea, hypertension, flushing, hypophosphatemia, dizziness; rare: hypersensitivity reactions.


Half-life: 7–12 hours.

How Supplied:

Single-use vial (15mL)—1, 2

Pricing for INJECTAFER

15ml of 750mg/15ml vial (Qty: 2)
Appx. price $2335